Sheila Umlauf
Biotechnology Associate II Yale Center for Molecular DiscoveryCards
About
Research
Publications
2024
Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer
Gunasekharan V, Lin H, Marczyk M, Rios-Hoyo A, Campos G, Shan N, Ahmed M, Umlauf S, Gareiss P, Raaisa R, Williams R, Cardone R, Siebel S, Kibbey R, Surovtseva Y, Pusztai L. Phosphoenolpyruvate carboxykinase-2 (PCK2) is a therapeutic target in triple-negative breast cancer. Breast Cancer Research And Treatment 2024, 208: 657-671. PMID: 39177932, DOI: 10.1007/s10549-024-07462-z.Peer-Reviewed Original ResearchMetabolic fluxTriple-negative breast cancerReduced metabolic fluxMDA-MB-231 cellsCell growth in vitroEnzyme assays in vitroMDA-MB-231Potential small molecule inhibitorsPyruvate carboxylaseGrowth in vitroSmall molecule inhibitorsIn silico screeningEnzyme assaysAssay in vitroEnzymatic assayCell lines in vitroEnzyme activityGrowth inhibitory activityBT-549Breast cancerIn vitro screeningBreast cell lines in vitroPhosphoenolpyruvateSignificant growth inhibitory activityLines in vitro
2022
Comprehensive Analysis of Metabolic Isozyme Targets in Cancer
Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, Shan NL, Blenman KRM, O'Meara TA, Umlauf S, Surovtseva YV, Muthusamy V, Rinehart J, Perry RJ, Kibbey R, Hatzis C, Pusztai L. Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. Cancer Research 2022, 82: 1698-1711. PMID: 35247885, PMCID: PMC10883296, DOI: 10.1158/0008-5472.can-21-3983.Peer-Reviewed Original ResearchConceptsPotential therapeutic targetAcetyl-CoA carboxylase 1Therapeutic targetCancer typesCell linesBreast cancer viabilityPatient-derived xenograftsNovel metabolic targetsCorresponding cell linesExpression patternsDrug treatmentMatching normal tissuesRelated commentaryTumor growthMalignant transformationSmall molecule inhibitionCancer viabilityCancer Cell Line EncyclopediaNormal tissuesMetabolic vulnerabilitiesCarboxylase 1Anticancer therapyCellular changesCell proliferationMetabolic reprogramming
2020
854 Functional drug screening identifies candidate synergistic combinations for CTCL therapy
Yumeen S, Mirza F, Lewis J, King A, Kim S, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 854 Functional drug screening identifies candidate synergistic combinations for CTCL therapy. Journal Of Investigative Dermatology 2020, 140: s111. DOI: 10.1016/j.jid.2020.03.870.Peer-Reviewed Original ResearchScreening Novel Agent Combinations to Expedite CTCL Therapeutic Development
Mirza FN, Yumeen S, Lewis JM, King ALO, Kim S, Carlson KR, Umlauf S, Surovtseva YV, Foss FM, Girardi M. Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development. Journal Of Investigative Dermatology 2020, 141: 217-221. PMID: 32534802, DOI: 10.1016/j.jid.2020.05.097.Peer-Reviewed Original ResearchJAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL
Yumeen S, Mirza FN, Lewis JM, King ALO, Kim SR, Carlson KR, Umlauf SR, Surovtseva YV, Foss FM, Girardi M. JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances 2020, 4: 2213-2226. PMID: 32437546, PMCID: PMC7252559, DOI: 10.1182/bloodadvances.2020001756.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaJAK inhibitionCTCL cellsMalignant cutaneous T-cell lymphomasAdvanced cutaneous T-cell lymphomaTreatment of CTCLAvailable systemic treatment optionsSkin-homing T lymphocytesSystemic treatment optionsT-cell lymphomaCTCL cell linesHistone deacetylase inhibitionGeneralized cytotoxic effectExpression of Bcl2Advanced diseaseSuch patientsPeripheral bloodTreatment optionsJAK/STAT pathwayT lymphocytesPreclinical assessmentTherapeutic targetStrong potentiationExtrinsic apoptosis pathwayDeacetylase inhibition
2019
676 Exploring novel therapeutic targets in the treatment of cutaneous T-cell lymphoma
Yumeen S, King A, Kim S, Lewis J, Carlson K, Umlauf S, Surovtseva Y, Foss F, Girardi M. 676 Exploring novel therapeutic targets in the treatment of cutaneous T-cell lymphoma. Journal Of Investigative Dermatology 2019, 139: s116. DOI: 10.1016/j.jid.2019.03.752.Peer-Reviewed Original Research
2014
Stress‐Related Alcohol Consumption in Heavy Drinkers Correlates with Expression of miR‐10a, miR‐21, and Components of the TAR‐RNA‐Binding Protein‐Associated Complex
Beech RD, Leffert JJ, Lin A, Hong KA, Hansen J, Umlauf S, Mane S, Zhao H, Sinha R. Stress‐Related Alcohol Consumption in Heavy Drinkers Correlates with Expression of miR‐10a, miR‐21, and Components of the TAR‐RNA‐Binding Protein‐Associated Complex. Alcohol Clinical And Experimental Research 2014, 38: 2743-2753. PMID: 25421511, PMCID: PMC4244644, DOI: 10.1111/acer.12549.Peer-Reviewed Original ResearchConceptsMiR-21Psychological stressMD subjectsAcute psychological stressReal-time polymerase chain reactionQuantitative real-time polymerase chain reactionGene expressionAlcohol intakeHD groupPeripheral bloodStress-related drinkingPolymerase chain reactionStimulus presentationModerate drinkersMD groupAlcohol-related cuesDrinking subjectsStress-induced drinkingAlcohol consumptionHeavy drinkersAlcohol dependenceAmount of beerMicroRNA-10aChain reactionMicroRNA-21
2013
Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS)
Beech RD, Leffert JJ, Lin A, Sylvia LG, Umlauf S, Mane S, Zhao H, Bowden C, Calabrese JR, Friedman ES, Ketter TA, Iosifescu DV, Reilly-Harrington NA, Ostacher M, Thase ME, Nierenberg A. Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS). The Pharmacogenomics Journal 2013, 14: 182-191. PMID: 23670706, DOI: 10.1038/tpj.2013.16.Peer-Reviewed Original ResearchConceptsPeripheral bloodTreatment responseLithium Treatment Moderate-Dose Use StudyLi respondersClinical responseTreatment initiationTreatment respondersMood symptomsLithium respondersEarly markerBipolar disorderRespondersBloodPatientsGene expression differencesSpecific roleSubjectsResponseBiochemical levelSymptomsDifferencesMonths
2012
Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation
Lowthert L, Leffert J, Lin A, Umlauf S, Maloney K, Muralidharan A, Lorberg B, Mane S, Zhao H, Sinha R, Bhagwagar Z, Beech R. Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithium-responders one month after treatment initiation. Biology Of Mood & Anxiety Disorders 2012, 2: 15. PMID: 22967286, PMCID: PMC3448519, DOI: 10.1186/2045-5380-2-15.Peer-Reviewed Original ResearchBCL2-antagonist/killer 1Insulin receptor substrate 2Pathway analysisBCL2 gene family membersGene family membersRegulation of apoptosisGene expression profilesPro-apoptotic genesAnti-apoptotic genesClinical responseBipolar disorderBlood gene expression profilesLevel of expressionMolecular basisTranscript probesExpression profilesGeneGo MetaCore softwareMetaCore softwarePeripheral blood gene expression profilesCell deathSubstrate 2GenesOpen-label treatmentGold standard medicationDifferential responseAltered Expression of Cytokine Signaling Pathway Genes in Peripheral Blood Cells of Alcohol Dependent Subjects: Preliminary Findings
Beech RD, Qu J, Leffert JJ, Lin A, Hong KA, Hansen J, Umlauf S, Mane S, Zhao H, Sinha R. Altered Expression of Cytokine Signaling Pathway Genes in Peripheral Blood Cells of Alcohol Dependent Subjects: Preliminary Findings. Alcohol Clinical And Experimental Research 2012, 36: 1487-1496. PMID: 22471388, PMCID: PMC3393821, DOI: 10.1111/j.1530-0277.2012.01775.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol DrinkingAlcoholismBlood CellsCytokinesDemographyDiagnostic and Statistical Manual of Mental DisordersEthnicityFemaleGene ExpressionGene Expression ProfilingHumansInterleukin-15InterleukinsJanus KinasesMaleMicroarray AnalysisMiddle AgedRecurrenceSignal TransductionSTAT Transcription FactorsYoung AdultConceptsGroups of subjectsMD subjectsAlcohol dependenceGeneGo MetaCore softwareEnd-organ damageChronic alcohol abusePeripheral blood cellsInnate immune responseAlcohol-dependent subjectsHeavy alcohol useT cell receptorPeripheral bloodClinical studiesImmune responseJanus kinase-signal transducerHigh riskImmune functionModerate drinkersHD subjectsAlcohol abuseAlcohol consumptionHeavy drinkersKinase-signal transducerDependent subjectsSignaling Pathway Genes